Dr. Alejandro Daniel Iglesias, MD

Dr. Iglesias practices at NYP Morgan Stanley Children's Hospital in New York, New York.

Dr. Iglesias' NPI, 1629050851, was assigned on November 15, 2005. Dr. Iglesias graduated from University of Buenos Aires in 1986. Dr. Iglesias' New York license number on file is 237706.

Dr. Iglesias' primary practice is NYP Morgan Stanley Children's Hospital, at 3959 Broadway, New York, NY 10032 in New York County. The practice phone is (201) 862-9107.

Dr. Iglesias' primary practice is NYP Morgan Stanley Children's Hospital in New York, New York. Dr. Iglesias is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Iglesias to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Iglesias practices, 2 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Iglesias' primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Iglesias is board certified in clinical biochemical genetics by the American Board of Medical Genetics and Genomics. Dmand AI has Dr. Iglesias' licenses on file in 2 states: New York and Connecticut.

Dmand AI lists hypercalcemia among the conditions Dr. Iglesias treats.

CMS data shows 11 Medicare services from Dr. Iglesias across 1 procedure code in 2024, all of them office visits, for 24 Medicare patients. Medicare paid $2,118 for them. Every service was in an office.

CMS counts 24 Medicare patients who saw Dr. Iglesias in 2024. 63% of them have high cholesterol, and 54% have high blood pressure. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Iglesias' median patient age at 33, with 60% women.

In 2024, Dr. Iglesias wrote 55 Medicare Part D claims. 51% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $149 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Iglesias for performance year 2024, reported through an alternative payment model (APM). Dr. Iglesias accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Iglesias as offering telehealth.

Dmand AI links 40 papers to Dr. Iglesias, published from 2013 to 2024. 2016 was the busiest year, with 6. The most frequent topics are Exome, Developmental Disabilities and Mutation, Missense. Dr. Iglesias has published most often in Am J Hum Genet. Dr. Iglesias' most frequent co-authors are Wendy Chung, MD, Kwame Anyane-Yeboa, MD and Kosuke Izumi, MD.

CMS Open Payments shows 26 general payments to Dr. Iglesias from 12 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 59% of the total. Horizon Pharma plc paid the most, $3,115.

Dr. Iglesias graduated from University of Buenos Aires in 1986.

Dr. Iglesias is in network with 13 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.